XpresCheck™ Opens COVID-19 Testing Facility at San Francisco International Airport
XpresCheck is a pop-up facility located pre-security, near the baggage claim area on the Arrivals level at Terminal 3. Nine separate testing rooms provide the capacity to administer over 500 tests per day. COVID-19 testing options include a Rapid Molecular COVID-19 Test, the standard Polymerase Chain Reaction (PCR) Test, and a new Rapid PCR test in the near future.
“We welcome the addition of an XpresCheck™ COVID-19 Pop-Up Testing Facility at SFO,” said Airport Director Ivar C. Satero. “As the first airport in the U.S. to launch an onsite rapid testing capability, we understand the importance of giving travelers convenient on-airport testing options. We thank both United Airlines and the XpresSpa Group for bringing this concept to SFO.”
Twitter: @xprescheck and Instagram: @realxprescheck
About United Airlines
United's shared purpose is "Connecting People. Uniting the World." For more information, visit united.com, follow @United on Twitter and Instagram or connect on Facebook. The common stock of United's parent, United Airlines Holdings, Inc., is traded on the Nasdaq under the symbol "UAL".
SFO wants you to Travel Well. SFO works with local, state, and federal health officials to protect against COVID-19. Measures include enhanced cleaning protocols, hundreds of hand sanitizer stations, physical barriers, face coverings for everyone, and physical distancing. To learn more visit flysfo.com/travel-well.
SFO offers nonstop service to
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to
Source: XpresSpa Group, Inc.